These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23802627)

  • 1. Investigational cytokine-targeted therapies for ulcerative colitis.
    Monteleone G; Pallone F; Caprioli F
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1123-32. PubMed ID: 23802627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.
    Lawrance IC
    Expert Opin Investig Drugs; 2015 Jun; 24(6):761-8. PubMed ID: 25719407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis.
    Guimbaud R; Bertrand V; Chauvelot-Moachon L; Quartier G; Vidon N; Giroud JP; Couturier D; Chaussade S
    Am J Gastroenterol; 1998 Dec; 93(12):2397-404. PubMed ID: 9860399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive and biologic therapy for ulcerative colitis.
    Ardizzone S; Cassinotti A; de Franchis R
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):449-67. PubMed ID: 23163556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
    Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids.
    Nishimura R; Shirasaki T; Tsuchiya K; Miyake Y; Watanabe Y; Hibiya S; Watanabe S; Nakamura T; Watanabe M
    J Gastroenterol; 2019 Jul; 54(7):608-620. PubMed ID: 30599053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging oral drug options for ulcerative colitis.
    Salvatori S; Neri B; Marafini I; Brigida M; Monteleone G
    Expert Opin Emerg Drugs; 2023 Dec; 28(3):191-201. PubMed ID: 37668153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
    Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of non-biological treatments in Ulcerative Colitis.
    Troncone E; Monteleone G
    Expert Opin Drug Saf; 2017 Jul; 16(7):779-789. PubMed ID: 28608717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis.
    Márquez L; Shen C; Cleynen I; De Hertogh G; Van Steen K; Machiels K; Perrier C; Ballet V; Organe S; Ferrante M; Henckaerts L; Galicia G; Rutgeerts P; Ceuppens JL; Vermeire S
    Gut; 2012 Apr; 61(4):528-34. PubMed ID: 21708824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New lessons: classic treatments, expanding options in ulcerative colitis.
    Hanauer SB
    Colorectal Dis; 2006 May; 8 Suppl 1():20-4. PubMed ID: 16594960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
    Cohen RD; Woseth DM; Thisted RA; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development.
    Caballol B; Gudiño V; Panes J; Salas A
    Expert Opin Investig Drugs; 2021 Sep; 30(9):931-946. PubMed ID: 34365869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: Ulcerative colitis, smoking and nicotine therapy.
    Lunney PC; Leong RW
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):997-1008. PubMed ID: 23072629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxazolone-induced murine model of ulcerative colitis.
    Wang X; Ouyang Q; Luo WJ
    Chin J Dig Dis; 2004; 5(4):165-8. PubMed ID: 15612886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th17-cytokine blockers as a new approach for treating inflammatory bowel disease.
    Monteleone I; Pallone F; Monteleone G
    Ann Med; 2011 May; 43(3):172-8. PubMed ID: 21114459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa.
    Zwolinska-Wcislo M; Brzozowski T; Budak A; Kwiecien S; Sliwowski Z; Drozdowicz D; Trojanowska D; Rudnicka-Sosin L; Mach T; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2009 Mar; 60(1):107-18. PubMed ID: 19439813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.